Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Condom usage is down for everyone in the U.S., but researchers say the trend is especially stark among teens and young adults ...

Condom usage is down for everyone in the U.S., but researchers say the trend is especially stark among teens and young adults ...

HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV ...

Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper ...

Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.

How supplies of GLP-1 drugs could be at risk as a result of the dockworker strike occurring across the East and Gulf coasts: ...

It's hard to miss the overflowing bowl of condoms at the entrance of the gym.Some University of Mississippi students walking ...

The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...

Lenacapravir is a major advance, since it provides a highly effective PrEP option that can be delivered subcutaneously twice a year.

A new report finds there is a decline in condom usage because of access to other contraceptives and drugs that prevent STIs.